Literature DB >> 22877654

Ten common questions (and their answers) about off-label drug use.

Christopher M Wittich1, Christopher M Burkle, William L Lanier.   

Abstract

The term off-label drug use (OLDU) is used extensively in the medical literature, continuing medical education exercises, and the media. Yet, we propose that many health care professionals have an underappreciation of its definition, prevalence, and implications. This article introduces and answers 10 questions regarding OLDU in an effort to clarify the practice's meaning, breadth of application, acceptance, and liabilities. Off-label drug use involves prescribing medications for indications, or using a dosage or dosage form, that have not been approved by the US Food and Drug Administration. Since the Food and Drug Administration does not regulate the practice of medicine, OLDU has become common. It occurs in every specialty of medicine, but it may be more common in areas of medicine in which the patient population is less likely to be included in clinical trials (eg, pediatric, pregnant, or psychiatric patients). Pharmaceutical companies are not allowed to promote their medications for an off-label use, which has lead to several large settlements for illegal marketing. To limit liability, physicians should prescribe medications only for indications that they believe are in the best interest of the patient. In addition, health care professionals should educate themselves about OLDU to weigh the risks and benefits and provide the best possible care for their patients.
Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22877654      PMCID: PMC3538391          DOI: 10.1016/j.mayocp.2012.04.017

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  41 in total

1.  Treatment options for female sexual arousal disorder: part II.

Authors:  Melissa Feldhaus-Dahir
Journal:  Urol Nurs       Date:  2010 Jul-Aug

2.  Off-label and unlicensed medication use and associated adverse drug events in a pediatric emergency department.

Authors:  Hanna Phan; Marc Leder; Matthew Fishley; Matthew Moeller; Milap Nahata
Journal:  Pediatr Emerg Care       Date:  2010-06       Impact factor: 1.454

3.  Did the removal of the indication of nocturnal enuresis for intranasal desmopressin change prescribing practice?

Authors:  Falk Hoffmann; Gerd Glaeske; Christian Steuber
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11-11       Impact factor: 2.890

Review 4.  Off-label use of azathioprine in dermatology: a systematic review.

Authors:  Mandy E Schram; Rinke J Borgonjen; Cathelijne M J M Bik; Jan G van der Schroeff; Jannes J E van Everdingen; Phyllis I Spuls
Journal:  Arch Dermatol       Date:  2011-04

5.  Enforcement actions involving Medicaid fraud and abuse, 1996-2009.

Authors:  Zaina P Qureshi; Ying Liu; Oliver Sartor; Yong H Chu; Charles L Bennett
Journal:  Arch Intern Med       Date:  2011-04-25

6.  The ClinicalTrials.gov results database--update and key issues.

Authors:  Deborah A Zarin; Tony Tse; Rebecca J Williams; Robert M Califf; Nicholas C Ide
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

Review 7.  Erythromycin as a prokinetic agent: risk factors.

Authors:  S Berthet; B Charpiat; J Y Mabrut
Journal:  J Visc Surg       Date:  2010-07-23       Impact factor: 2.043

8.  Increasing off-label use of antipsychotic medications in the United States, 1995-2008.

Authors:  G C Alexander; S A Gallagher; A Mascola; R M Moloney; R S Stafford
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-01-06       Impact factor: 2.890

9.  Off-label medication use in adult critical care patients.

Authors:  Ishaq Lat; Scott Micek; Jeffrey Janzen; Henry Cohen; Keith Olsen; Curtis Haas
Journal:  J Crit Care       Date:  2010-08-16       Impact factor: 3.425

10.  Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.

Authors:  Aaron S Kesselheim; Michelle M Mello; David M Studdert
Journal:  PLoS Med       Date:  2011-04-05       Impact factor: 11.069

View more
  51 in total

Review 1.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

2.  Dispensing medical countermeasures: emergency use authorities and liability protections.

Authors:  Charles G Kels
Journal:  Health Secur       Date:  2015-03-26

Review 3.  Ethics codes and use of new and innovative drugs.

Authors:  Jan Borysowski; Hans-Jörg Ehni; Andrzej Górski
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

Review 4.  Administration of dry powders during respiratory supports.

Authors:  Wei-Ren Ke; Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Patricia Tang; Lan Chen; Donghao Chen; Hak-Kim Chan
Journal:  Ann Transl Med       Date:  2021-04

Review 5.  The Economics and Regulation of PRP in the Evolving Field of Orthopedic Biologics.

Authors:  Ian A Jones; Ryan C Togashi; C Thomas Vangsness
Journal:  Curr Rev Musculoskelet Med       Date:  2018-12

6.  Off-label, but on-target: use of regadenoson with exercise.

Authors:  Robert C Hendel; Lauren Frost
Journal:  J Nucl Cardiol       Date:  2013-04       Impact factor: 5.952

7.  The high cost of cancer drugs and what we can do about it.

Authors:  Mustaqeem Siddiqui; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

8.  Integrating value assessment into discussions about the price of cancer drugs.

Authors:  Craig Bunnell
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

9.  Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth.

Authors:  Tanya L Kowalczyk Mullins; Gregory Zimet; Michelle Lally; Jessica A Kahn
Journal:  AIDS Patient Care STDS       Date:  2016-07       Impact factor: 5.078

10.  Choosing Wisely: Wise Choices in Psychiatry.

Authors:  Douglas Urness; Naomi J Parker; Mark J Rapoport; Thomas C R Wilkes
Journal:  Can J Psychiatry       Date:  2016-04-06       Impact factor: 4.356

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.